Pelthos Therapeutics PTHS ZELSUVMI Royalty Agreement — Income received through royalty
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pelthos Therapeutics in its filing.
Tagged under the XBRL concept pths:RevenueRemainingPerformanceObligationVariableConsiderationPercentOfNonRoyaltySublicenseIncome.
The source filing: Pelthos Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001919246-26-000070
first commercial sale of the ZELSUVMI, a $5,000 milestone; (iv) upon the occurrence obtaining a threshold of $35,000 in aggregate net sales during four consecutive calendar quarters, a $5,000 milestone; and (vi) 30% of all non-royalty sublicense income received by the Company or its affiliates from any sublicensee. The first commercial sale milestone has been accrued within accrued expenses on the condensed consolidated balance sheets as of March 31, 2026.
Item 1. Financial Statements (unaudited)
FAQ
- What is Pelthos Therapeutics's ZELSUVMI royalty agreement — income received through royalty?
- Pelthos Therapeutics (PTHS) reported ZELSUVMI royalty agreement — income received through royalty of 30% in Q1 2026.
- How has Pelthos Therapeutics's ZELSUVMI royalty agreement — income received through royalty changed year-over-year?
- Pelthos Therapeutics's ZELSUVMI royalty agreement — income received through royalty increased by 300.0% year-over-year, from 7.5% to 30%.
- What does ZELSUVMI royalty agreement — income received through royalty mean?
- This represents the actual cash or revenue recognized from royalty streams generated by a licensed product or technology. It provides a direct measure of the commercial performance and revenue-generating capability of the underlying intellectual property.
Ask your AI about Pelthos Therapeutics's zelsuvmi royalty agreement — income received through royalty.
Connect your AI assistant and compare it to peers, right in your chat.
